Page 162 - 2021_07-Haematologica-web

Ferrata Storti Foundation
Haematologica 2021 Volume 106(7):1932-1942
Non-Hodgkin Lymphoma
Outcomes of Burkitt lymphoma with central nervous system involvement: evidence from a large multicenter cohort study
Adam S. Zayac,1* Andrew M. Evens,2* Alexey Danilov,3 Stephen D. Smith,4 Deepa Jagadeesh,5 Lori A. Leslie,6 Catherine Wei,2 Seo-Hyun Kim,7 Seema Naik,8 Suchitra Sundaram,9 Nishitha Reddy,10 Umar Farooq,11 Vaishalee P Kenkre,12 Narendranath Epperla,13 Kristie A. Blum,14 Nadia Khan,15 Daulath Singh,16 Juan P. Alderuccio,17 Amandeep Godara,18 Maryam Sarraf Yazdy,19 Catherine Diefenbach,20 Emma Rabinovich,21 Gaurav Varma,22 Reem
23 5 17 23 22 Karmali, Yusra Shao, Asaad Trabolsi, Madelyn Burkart, Peter Martin,
Sarah Stettner,21 Ayushi Chauhan,19 Yun Kyong Choi,20 Allandria Straker- Edwards,15 Andreas Klein,18 Michael C. Churnetski,14 Kirsten M. Boughan,24 Stephanie Berg,16 Bradley M Haverkos,25 Victor M. Orellana-Noia,26 Christopher D'Angelo,12 David A Bond,13 Seth M. Maliske,11 Ryan Vaca,8 Gabriella Magarelli,6 Amy Sperling,4 Max J. Gordon,3 Kevin A. David,2 Malvi Savani,27 Paolo Caimi,24 Manali Kamdar,25 Matthew A. Lunning,28 Neil Palmisiano,29 Parameswaran Venugopal,7 Craig A Portell,26 Veronika Bachanova,27 Tycel Phillips,30 Izidore S. Lossos17 and Adam J. Olszewski1
Presented in part as an Oral Presentation at the 61st American Society of Hematology Meeting & Exposition, December 7-10, 2019, in Orlando, FL, USA.
1Lifespan Cancer Institute, Alpert Medical School of Brown University, Providence, RI; 2Rutgers Cancer Institute of New Jersey, Robert Wood Johnson University Hospital, New Brunswick, NJ; 3Knight Cancer Institute, Oregon Health & Science University, Portland, OR; 4University of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA; 5Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH; 6John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ; 7Rush University Medical Center, Chicago, IL; 8Penn State Cancer Institute, Penn State University College of Medicine, Hershey, PA; 9Roswell Park Comprehensive Cancer Center, Buffalo, NY; 10Vanderbilt University Medical Center, Nashville, TN; 11University of Iowa Carver College of Medicine, Iowa City, IA; 12University of Wisconsin Carbone Cancer Center, Madison, WI; 13The Ohio State University Comprehensive Cancer Center, Columbus, OH; 14Winship Cancer Institute, Emory University, Atlanta, GA; 15Fox Chase Cancer Center, Philadelphia, PA; 16Loyola University Medical Center, Loyola University Chicago, Maywood, IL; 17Sylvester Comprehensive Cancer Center, University of Miami School of Medicine, Miami, FL; 18Tufts Medical Center, Boston, MA; 19Lombardi Comprehensive Cancer Center, Georgetown University Hospital, Washington, DC; 20New York University School of Medicine, Perlmutter Cancer Center, New York, NY; 21University of Illinois at Chicago, Chicago, IL; 22Weill Cornell Medical College, New York, NY; 23Northwestern University, Chicago, IL; 24University Hospitals Seidman Cancer Center, Cleveland, OH; 25University of Colorado Cancer Center, Aurora, CO; 26University of Virginia School of Medicine, Charlottesville, VA; 27University of Minnesota, Minneapolis, MN; 28University of Nebraska Medical Center, Omaha, NE; 29Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA and 30University of Michigan, Ann Arbor, MI, USA
*ASZ and AME contributed equally as co-first authors.
ABSTRACT
Central nervous system (CNS) involvement in Burkitt lymphoma poses a major therapeutic challenge, and the relative ability of contemporary regimens to treat CNS involvement remains uncertain. We describe the prognostic significance of CNS involvement and the incidence of CNS recurrence/progression after contemporary immunochemotherapy using real-world clinicopathological data from adults with Burkitt lymphoma diagnosed between 2009 and 2018 in 30 institutions in the USA. We examined associations between baseline CNS involvement, patients’ characteristics, complete response rates, and sur- vival. We also examined risk factors for CNS recurrence. Of 641 patients (aged 18 to 88 years), 120 (19%) had CNS involvement. CNS involvement was independently associated with human immunodeficiency virus infection, poor performance status, involvement of ≥2 extranodal sites, and bone marrow involvement. Selection of the first-line treatment regi- men was unaffected by CNS involvement (P=0.93). Patients with CNS
Correspondence:
ADAM J. OLSZEWSKI
adam_olszewski@brown.edu
Received: September 6, 2020. Accepted: December 22, 2020. Pre-published: February 4, 2021.
https://doi.org/10.3324/haematol.2020.270876
©2021 Ferrata Storti Foundation
Material published in Haematologica is covered by copyright. All rights are reserved to the Ferrata Storti Foundation. Use of published material is allowed under the following terms and conditions: https://creativecommons.org/licenses/by-nc/4.0/legalcode. Copies of published material are allowed for personal or inter- nal use. Sharing published material for non-commercial pur- poses is subject to the following conditions: https://creativecommons.org/licenses/by-nc/4.0/legalcode, sect. 3. Reproducing and sharing published material for com- mercial purposes is not allowed without permission in writing from the publisher.
1932
haematologica | 2021; 106(7)
ARTICLE